印度新兴感染疾病诊断市场（2023-2033）：流行病学、用途、技术、感染类型、疾病类型和最终用户的分析和预测

印度新兴感染疾病诊断市场规模预计将从 2022 年的 3.391 亿美元成长到 2033 年的 9.827 亿美元，预测期内年复合成长率为 10.29%。

印度新兴的感染疾病诊断市场正处于新兴阶段。近年来，诊断方法得到了改进和创新，特别是随着次世代定序的出现以及对 COVID-19 等快速检测的需求而不断增加。提供更快、更有效率、更具成本效益的诊断的新技术和设备可能会重振市场并推动其进入成长阶段。

按用途，实验室测试部门将在 2022 年引领市场。实验室检测在感染疾病的诊断和管理中发挥重要作用。此外，从技术角度来看，PCR部门将在 2022 年引领市场。 PCR现在在世界各地的实验室中得到应用，因为它可以进一步扩增DNA并分析少量核酸。

印度新兴感染疾病诊断市场：概述

主要市场统计数据
预测期	2023-2033
2023年评估	3.691 亿美元
2033年预测	9.827 亿美元
年复合成长率	10.29%

本报告调查了印度新兴感染疾病诊断市场，并提供了市场概况、市场成长的各种影响因素分析、市场规模趋势和预测、各个细分市场的详细分析、竞争形势以及主要企业。进行了总结。

目录

第1章产品定义

第2章市场范围

第3章调查方法

第4章市场概况

• 市场概况
  • 印度感染疾病流行病学
  • 最值得推荐的感染疾病诊断平台
  • 感染疾病诊断新兴技术的时间表
  • 新兴感染疾病诊断技术的优点和局限性
  • 新兴感染疾病即时诊断的优点和局限性

第5章印度新兴感染疾病诊断市场：市场动态

• 影响分析
• 市场促进因素
• 市场抑制因素
• 市场机会

第6章印度新兴感染疾病诊断市场：依用途

• 概述
• 试验
• POC（护理点）测试

第7章印度新兴感染疾病诊断市场：依技术分类

• 概述
• 聚合酶炼式反应 (PCR)
  • 逆转录聚合酶连锁反应 (RT-PCR)
  • 数位PCR
• 免疫诊断
• 恒温核酸增幅技术（INAAT）
• 下一代定序（NGS）
• 其他技术

第8章印度新兴感染疾病诊断市场：按感染疾病类型

• 概述
• 细菌
• 病毒性的
• 真菌的
• 其他（寄生虫等）

第9章印度新兴感染疾病诊断市场：依疾病类型

• 概述
• 呼吸道感染疾病
• 胃肠道感染疾病
• 性行为感染感染（STI）
• 神经系统感染疾病
• 移植后感染疾病
• 其他的

第10章印度新兴感染疾病诊断市场：依最终用户分类

• 概述
• 医院/诊所
• 诊断实验室
• 其他的

第11章市场：竞争基准化分析与公司概况

• 竞争形势
• 市场占有率分析（按公司）
• 公司简介
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Co-Diagnostics, Inc.
  • DANAHER CORPORATION
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
• 新兴企业简介
  • Trivitron Healthcare
  • Genes2Me
  • CrisprBits
  • D-NOME Pvt Ltd

“The India Emerging Infectious Disease Diagnostics Market to Reach $982.7 Million by 2033.”

India Emerging Infectious Disease Diagnostics Market Overview

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$369.1 Million
2033 Forecast	$982.7 Million
CAGR	10.29%

The India emerging infectious disease diagnostics market is projected to experience substantial growth over the forecast period 2023-2033. Moreover, the market value for 2022 was estimated to be $339.1 million and is expected to reach $982.7 million by 2033, showcasing a CAGR of 10.29% during the forecast period.

Market Lifecycle Stage

The India emerging infectious disease diagnostics market is in an emerging phase. Recent years have seen improvements and innovations in diagnostic methods, particularly with the advent of next-generation sequencing and the growing demand for rapid testing (such as in the case of the COVID-19 pandemic). New technologies and devices that offer faster, more efficient, or more cost-effective extraction could rejuvenate the market and push it back toward a growth phase.

Industry Impact

The India emerging infectious disease diagnostics market has proven to be a cornerstone in the evolution of modern biotechnology, clinical diagnostics, and research of different pathogens. Infectious disease diagnostics have a significant impact on various aspects of healthcare and public health. Here are some key impacts:

Accurate and Timely Diagnosis: Infectious disease diagnostics enable healthcare providers to accurately identify the causative agents of infections, leading to timely and appropriate treatment. Early diagnosis helps improve patient outcomes, reduce morbidity and mortality rates, and prevent the spread of infectious diseases.

Effective Patient Management: Diagnostic tests provide critical information for healthcare providers to guide patient management strategies. These tests help determine the most effective treatment options, including the selection of appropriate antimicrobial therapies and the implementation of infection control measures. This leads to better patient care and improved healthcare outcomes.

Public Health Surveillance and Outbreak Control: Infectious disease diagnostics play a crucial role in public health surveillance. By identifying and monitoring infectious agents, diagnostic tests contribute to the detection and tracking of disease outbreaks. This information helps public health authorities implement timely interventions, such as contact tracing, isolation measures, and targeted vaccination campaigns, to control the spread of infections.

Research and Development: Infectious disease diagnostics drive research and development efforts to improve existing diagnostic methods and develop new technologies. Ongoing advancements in diagnostics contribute to the discovery of novel biomarkers, the enhancement of diagnostic accuracy and sensitivity, and the integration of innovative approaches such as molecular techniques, biosensors, and artificial intelligence.

Market Segmentation:

Segmentation 1: by Application

• Laboratory Testing
• Point-of-Care Testing

Laboratory Testing to Dominate the India Emerging Infectious Disease Diagnostics Market (by Application)

Based on application, the laboratory testing segment dominated the India emerging infectious disease diagnostics market in FY2022. Laboratory testing plays a crucial role in the diagnosis and management of infectious diseases. It involves the analysis of patient samples, such as blood, urine, sputum, or tissue, to detect the presence of infectious agents. Microbiological culture is a common technique that involves incubating patient samples on specific growth media to isolate and identify bacteria, fungi, or parasites, which can then be visualized through microscopy.

Segmentation 2: by Technology

• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Next-Generation Sequencing (NGS)
• Immunodiagnostics
• Other Technologies

PCR to Dominate the India Emerging Infectious Disease Diagnostics Market (by Technology)

Based on technology, the India emerging infectious disease diagnostics market was dominated by the PCR segment in FY2022. Nowadays, PCR is usually used in several laboratories around the world, as it amplifies DNA further, allowing the analysis of even small amounts of nucleic acid. With growing technological advancements in molecular biology techniques, PCR has been utilized in several fields, including disease diagnosis, DNA profiling, precision medicine, and gene expression.

Next-generation sequencing (NGS) has revolutionized infectious disease diagnosis by enabling comprehensive and high-throughput analysis of pathogen genomes. Whole genome sequencing (WGS) allows the sequencing of entire pathogen genomes, providing detailed information about genetic variations, antimicrobial resistance genes, and virulence factors. It can identify and characterize pathogens, track outbreaks, and analyze their evolutionary patterns.

Other emerging technologies anticipated to register significant growth include technologies such as digital PCR, INAAT, and clustered regularly interspaced short palindromic repeats (CRISPR).

• Digital PCR is an advanced molecular diagnostic technique used for infectious disease diagnostics. It enables the absolute quantification of target nucleic acids by partitioning the PCR reaction into thousands of individual reactions.
• INAAT has emerged as a valuable tool for infectious disease diagnostics. INAAT includes technologies such as loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA), which enable rapid and sensitive detection of pathogens without the need for complex equipment or multiple temperature cycles.
• CRISPR is a relatively new technology, and while it has been leveraged for gene editing and therapeutic purposes ever since the invention of CRISPR/Cas9 gene editing in 2011, it was only in 2016 that CRISPR-Cas systems were first developed to identify nucleic acids for molecular diagnostics.

Segmentation 3: by Type of Infection

• Bacterial
• Viral
• Fungal
• Other Infections (Parasitic etc)

Bacterial and Viral Segments to Dominate the India Emerging Infectious Disease Diagnostics Market (by Type of Infection)

Based on type of infection, bacterial infectious disease diagnosis involves various methods and techniques to identify the presence of bacterial pathogens in clinical samples. Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.

Viruses have the ability to mutate and, therefore, can lead to the re-emergence of diseases even after one form of the virus has been eradicated or managed. Molecular diagnostic companies are therefore focused on developing tests that can detect a wide range of viruses. Some of the common infections caused by viruses include influenza, genital herpes, COVID-19, hepatitis, mumps, rubella, gastroenteritis, Zika disease, and ebola disease, among others.

Segmentation 4: by Disease Type

• Respiratory Infections
• Gastrointestinal Infections
• Sexually Transmitted Infections (STIs)
• Neurological Infections
• Post-Transplant Infections
• Other Infections

Respiratory Infections to Dominate the India Emerging Infectious Disease Diagnostics Market (by Disease Type)

A vast majority of molecular diagnostic companies offer tests for various kinds of bacteria and viruses responsible for causing respiratory infections. Moreover, the COVID-19 pandemic led to the development of a wide range of tests employing conventional technologies such as reverse transcriptase PCR (RT-PCR) and even leveraging emerging technologies such as RT-LAMP and CRISPR. Several companies now offer multiplex assays that test for influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 virus.

Segmentation 5: by End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Other End Users

Hospitals and Clinics and Diagnostic Laboratories to Dominate the India Emerging Infectious Disease Diagnostics Market (by End User)

Based on end users, the hospitals and clinics and diagnostic laboratories segments accounted for the largest share of the India emerging infectious disease diagnostics market in FY2022. Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing. In addition to point-of-care testing (POCT), which provides immediate results for rapid diagnosis and management, hospitals and clinics may also rely on laboratory testing for comprehensive analysis. Some healthcare facilities have on-site laboratories equipped with state-of-the-art diagnostic technologies, while others collaborate with external diagnostic laboratories for specialized testing. These laboratory facilities employ various methods, including molecular techniques such as PCR and sequencing, serological assays, and culture-based methods to identify and characterize infectious agents accurately.

Recent Developments in the India Emerging Infectious Disease Diagnostics Market

• In February 2023, Thermo Fisher Scientific Inc. and Mylab announced a pact on test kits for infectious diseases.

• In February 2023, Biotech startup CrisprBits raised $250,000 in a pre-seed funding round to support the development and commercialization of its CRISPR-based tests.

• In February 2023, the Food and Drug Administration (FDA) authorized the Xpert Mpox test by Cepheid (parent: DANAHER CORPORATION) for emergency use.

• In August 2022, Bio-Rad Laboratories, Inc. acquired Curiosity Diagnostics to gain access to PCR ONE, a technology being developed by Curiosity Diagnostics, which can quickly detect a broad range of pathogens.

• In June 2021, Hologic, Inc. completed the acquisition of Mobidiag to expand its capabilities in molecular diagnostics.

• In January 2023, CrisprBits developed India's first CRISPR-based SARS-CoV-2 test with Omicron detection.

• In March 2023, an India-based startup, Mylab Discovery Solutions Pvt. Ltd., entered into a joint venture with AstraGene LLC, the U.A.E.'s first molecular diagnostics manufacturing company to develop molecular diagnostics in the U.A.E. and Kuwait.

• In November 2022, Bio-Rad Laboratories, Inc. and NuProbe entered into an exclusive licensing agreement for digital PCR applications.

Demand - Drivers, Restraints, and Opportunities

Market Drivers:

Rising Incidence of Emerging Infectious Diseases in India: The incidence of emerging infectious diseases in India has witnessed a steady rise in recent years, contributing significantly to the expansion of the country's emerging infectious disease diagnostics market. India emerging infectious disease diagnostics market has experienced substantial growth due to multiple factors. In addition to increased awareness and government initiatives, the country's past encounters with outbreaks such as Zika, Nipah, and the COVID-19 pandemic have underscored the critical importance of preparedness. As a result, hospitals, laboratories, and healthcare institutions have been channeling resources into advanced diagnostic technologies to detect emerging infectious diseases swiftly and accurately.

Market Restraints:

Inadequate Healthcare Infrastructure and Facilities: The India emerging infectious disease diagnostics market faces significant constraints due to inadequate healthcare infrastructure and facilities. These challenges could have a substantial impact on the ability to effectively diagnose and manage infectious diseases in the country.

For instance, the presence of limited healthcare infrastructure in many parts of India, particularly in rural and remote areas, poses a significant hurdle. These regions often lack well-equipped laboratories and diagnostic facilities, making it difficult to conduct timely and accurate diagnostic tests. As a result, individuals in these underserved areas may not have access to the diagnostics they need, which can lead to delayed diagnoses and increased disease transmission.

Market Opportunities:

Development of Technologically Advanced Platforms in India for Diagnosis: The development of technologically advanced diagnostic platforms in India represents a significant opportunity for players in the emerging infectious disease diagnostics market. The development of advanced diagnostic platforms can help address some of the existing constraints in the healthcare system, such as inadequate healthcare infrastructure and limited access to diagnostics in rural and remote areas.

These advancements include the development of molecular diagnostics, point-of-care testing, immunoassays, and automated systems, among others. These advancements also provide rapid and accurate results, enabling healthcare professionals to make timely treatment decisions.

How can this report add value to an organization?

Workflow/Innovation Strategy: The India emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: In the India emerging infectious disease diagnostics market product launches, upgradations, and approvals accounted for the maximum number of key developments, i.e., over 75.89% of the total developments in the India emerging infectious disease diagnostics market, as of September 2023.

Competitive Strategy: The India emerging infectious disease diagnostics market is fragmented with several established as well as emerging players. Key players in the India emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2022. The historical year analysis has been done from FY2020 to FY2021, and the market size has been calculated for FY2022 and projected for the period 2023-2033.
• The geographical distribution of the market revenue is estimated to be the same as the company's net revenue distribution. All the numbers are adjusted off to two digits after decimal for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. CAGR is calculated from 2023 to 2033.
• The market has been mapped based on different types of products available in the market and based on several indications. All the key companies that have a significant number of offerings to the India emerging infectious disease diagnostics market have been considered and profiled in the report.
• In the study, the primary respondent's verification has been considered to finalize the estimated market for the India emerging infectious disease diagnostics market.
• The latest annual reports of each market player have been taken into consideration for market revenue calculation.
• Market strategies and developments of key players have been considered for the calculation of sub-segment split.
• The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company if stated.

Primary Research

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding of the numbers of the various markets for market type

Secondary Research

Open Sources

• National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), Global Burden Disease (GBD), World Health Organization (WHO), and Indian Council of Medical Research (ICMR)
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolio
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases

The key data points taken from the secondary sources include:

• Segmentations, split-ups, and percentage shares
• Data for market value
• Key industry trends of the top players in the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

Infectious disease diagnostics encompass a range of methods and techniques used to identify and detect infectious agents in individuals suspected of having an infection. These diagnostics play a vital role in timely diagnosis and accuracy, enabling appropriate treatment decisions and public health interventions.

There are two major approaches in the field; one is microbiological culture, which is a fundamental approach in which patient specimens are cultured on specialized growth media to isolate and identify specific pathogens. This technique allows for the determination of the causative organism and the assessment of its antimicrobial susceptibility. Molecular diagnostics, another important approach, utilizes techniques such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) to detect the genetic material of the infectious agent. This enables highly sensitive and specific identification of pathogens, even at low concentrations.

Some of the prominent companies in this market are:

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

Table of Contents

1 Product Definition

• 1.1 Inclusion and Exclusion Criteria

2 Market Scope

• 2.1 Scope of the Study
• 2.2 Key Questions Answered in the Report

3 Research Methodology

4 Market Overview

• 4.1 Market Overview
  • 4.1.1 Epidemiology of Infectious Diseases in India
    • 4.1.1.1 Respiratory Infections
      • 4.1.1.1.1 Influenza A and B
        • 4.1.1.1.1.1 Incidence
        • 4.1.1.1.1.2 Diagnosis Rate
        • 4.1.1.1.1.3 Target Patient Pool
      • 4.1.1.1.2 Respiratory Syncytial Virus
        • 4.1.1.1.2.1 Incidence
        • 4.1.1.1.2.2 Diagnosis Rate
        • 4.1.1.1.2.3 Target Patient Pool
      • 4.1.1.1.3 Mycoplasma Infections
        • 4.1.1.1.3.1 Incidence
        • 4.1.1.1.3.2 Diagnosis Rate
        • 4.1.1.1.3.3 Target Patient Pool
      • 4.1.1.1.4 Pertussis
        • 4.1.1.1.4.1 Incidence
        • 4.1.1.1.4.2 Diagnosis Rate
        • 4.1.1.1.4.3 Target Patient Pool
    • 4.1.1.2 Sexual Transmitted Infections (STIs)
      • 4.1.1.2.1 Hepatitis B Infection
        • 4.1.1.2.1.1 Incidence
        • 4.1.1.2.1.2 Diagnosis Rate
        • 4.1.1.2.1.3 Target Patient Pool
      • 4.1.1.2.2 HIV-AIDS
        • 4.1.1.2.2.1 Incidence
        • 4.1.1.2.2.2 Diagnosis Rate
        • 4.1.1.2.2.3 Population Tested for HIV
      • 4.1.1.2.3 HPV Infection
        • 4.1.1.2.3.1 Incidence
        • 4.1.1.2.3.2 Diagnosis Rate
        • 4.1.1.2.3.3 Target Patient Pool
      • 4.1.1.2.4 Herpes
        • 4.1.1.2.4.1 Incidence
        • 4.1.1.2.4.2 Diagnosis Rate
        • 4.1.1.2.4.3 Target Patient Pool
      • 4.1.1.2.5 Gonorrhea
        • 4.1.1.2.5.1 Incidence
        • 4.1.1.2.5.2 Diagnosis Rate
        • 4.1.1.2.5.3 Target Patient Pool
      • 4.1.1.2.6 Syphilis
        • 4.1.1.2.6.1 Incidence
        • 4.1.1.2.6.2 Diagnosis Rate
        • 4.1.1.2.6.3 Target Patient Pool
    • 4.1.1.3 Gastrointestinal Infections
      • 4.1.1.3.1 Colitis
        • 4.1.1.3.1.1 Incidence
        • 4.1.1.3.1.2 Diagnosis Rate
        • 4.1.1.3.1.3 Target Patient Pool
      • 4.1.1.3.2 Peptic Ulcer
        • 4.1.1.3.2.1 Incidence
        • 4.1.1.3.2.2 Diagnosis Rate
        • 4.1.1.3.2.3 Target Patient Pool
      • 4.1.1.3.3 Diarrhea
        • 4.1.1.3.3.1 Incidence
        • 4.1.1.3.3.2 Diagnosis Rate
        • 4.1.1.3.3.3 Target Patient Pool
    • 4.1.1.4 Neurological Infections
      • 4.1.1.4.1 Meningitis
        • 4.1.1.4.1.1 Incidence
        • 4.1.1.4.1.2 Diagnosis Rate
        • 4.1.1.4.1.3 Target Patient Pool
      • 4.1.1.4.2 Encephalitis
        • 4.1.1.4.2.1 Incidence
        • 4.1.1.4.2.2 Diagnosis Rate
        • 4.1.1.4.2.3 Target Patient Pool
    • 4.1.1.5 Post-Transplant Infections
      • 4.1.1.5.1 CMV Infection
        • 4.1.1.5.1.1 Incidence
        • 4.1.1.5.1.2 Diagnosis Rate
        • 4.1.1.5.1.3 Target Patient Pool
    • 4.1.1.6 Sepsis
      • 4.1.1.6.1.1 Incidence
      • 4.1.1.6.1.2 Diagnosis Rate
      • 4.1.1.6.1.3 Target Patient Pool
    • 4.1.1.7 Antimicrobial Resistance (AMR)
      • 4.1.1.7.1 Microbe Resistance
      • 4.1.1.7.2 Key Causative Agents
      • 4.1.1.7.3 Preventive Measures to Limit AMR
      • 4.1.1.7.4 Challenges
  • 4.1.2 Most Preferred Platforms for Infectious Disease Diagnosis
    • 4.1.2.1 Rapid Antigen Test (RAT)
    • 4.1.2.2 Polymerase Chain Reaction (PCR)
    • 4.1.2.3 Next-Generation Sequencing (NGS)
  • 4.1.3 Timeline of Emerging Technologies for Infectious Disease Diagnostics
  • 4.1.4 Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
  • 4.1.5 Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics

5 India Emerging Infectious Disease Diagnostics Market: Market Dynamics

• 5.1 Impact Analysis
• 5.2 Market Drivers
  • 5.2.1 Rising Incidence of Emerging Infectious Diseases in India
  • 5.2.2 Increasing Adoption of Point-of-Care Testing in India
  • 5.2.3 Initiatives by Government and Organizations to Increase Awareness
• 5.3 Market Restraints
  • 5.3.1 Inadequate Healthcare Infrastructure and Facilities
  • 5.3.2 Lack of Skilled Personnel in Specialized Areas of Infectious Disease Control
• 5.4 Market Opportunities
  • 5.4.1 Development of Technologically Advanced Platforms in India for Diagnosis
    • 5.4.1.1 Isothermal Nucleic Acid Amplification Techniques (INAATs)
    • 5.4.1.2 Digital PCR (dPCR)
      • 5.4.1.2.1 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Technologies

6 India Emerging Infectious Disease Diagnostics Market (by Application), $Million, 2022-2033

• 6.1 Overview
• 6.2 Laboratory Testing
• 6.3 Point-of-Care Testing

7 India Emerging Infectious Disease Diagnostics Market (by Technology), $Million, 2022-2033

• 7.1 Overview
• 7.2 Polymerase Chain Reaction (PCR)
  • 7.2.1 Reverse Transcription PCR (RT-PCR)
  • 7.2.2 Digital PCR
• 7.3 Immunodiagnostics
• 7.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
• 7.5 Next-Generation Sequencing (NGS)
• 7.6 Other Technologies

8 India Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Million, 2022-2033

• 8.1 Overview
• 8.2 Bacterial
• 8.3 Viral
• 8.4 Fungal
• 8.5 Other Infections (Parasitic etc.)

9 India Emerging Infectious Disease Diagnostics Market (by Disease Type), 2023-2033

• 9.1 Overview
• 9.2 Respiratory Infections
• 9.3 Gastrointestinal Infections
• 9.4 Sexually Transmitted Infections (STIs)
• 9.5 Neurological Infections
• 9.6 Post-Transplant Infections
• 9.7 Other Infections

10 India Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033

• 10.1 Overview
• 10.2 Hospitals and Clinics
• 10.3 Diagnostic Laboratories
• 10.4 Other End Users

11 Markets - Competitive Benchmarking & Company Profiles

• 11.1 Competitive Landscape
  • 11.1.1 Overview
  • 11.1.2 Corporate Strategies
    • 11.1.2.1 Mergers and Acquisitions
    • 11.1.2.2 Synergistic Activities
    • 11.1.2.3 Business Expansions and Funding
  • 11.1.3 Business Strategies
    • 11.1.3.1 Product Launches/Upgradations/Approvals
• 11.2 Market Share Analysis (by Company)
• 11.3 Company Profiles
  • 11.3.1 Abbott Laboratories
    • 11.3.1.1 Company Overview
    • 11.3.1.2 Role of Abbott Laboratories in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.1.3 Financials
    • 11.3.1.4 Recent Developments
    • 11.3.1.5 Analyst Perspective
  • 11.3.2 Becton, Dickinson and Company
    • 11.3.2.1 Company Overview
    • 11.3.2.2 Role of Becton, Dickinson and Company in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.2.3 Financials
    • 11.3.2.4 Recent Developments
    • 11.3.2.5 Analyst Perspective
  • 11.3.3 bioMerieux S.A.
    • 11.3.3.1 Company Overview
    • 11.3.3.2 Role of bioMerieux S.A. in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.3.3 Financials
    • 11.3.3.1 Recent Developments
    • 11.3.3.2 Analyst Perspective
  • 11.3.4 Bio-Rad Laboratories, Inc.
    • 11.3.4.1 Company Overview
    • 11.3.4.2 Role of Bio-Rad Laboratories, Inc. in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.4.3 Financials
    • 11.3.4.4 Recent Developments
    • 11.3.4.5 Analyst Perspective
  • 11.3.5 Co-Diagnostics, Inc.
    • 11.3.5.1 Company Overview
    • 11.3.5.2 Role of Co-Diagnostics, Inc. in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.5.3 Recent Developments
    • 11.3.5.4 Analyst Perspective
  • 11.3.6 DANAHER CORPORATION
    • 11.3.6.1 Company Overview
    • 11.3.6.2 Role of DANAHER CORPORATION in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.6.3 Financials
    • 11.3.6.4 Recent Developments
    • 11.3.6.5 Analyst Perspective
  • 11.3.7 DiaSorin S.p.A.
    • 11.3.7.1 Company Overview
    • 11.3.7.2 Role of DiaSorin S.p.A. in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.7.3 Financials
    • 11.3.7.4 Recent Developments
    • 11.3.7.5 Analyst Perspective
  • 11.3.8 F. Hoffmann-La Roche Ltd
    • 11.3.8.1 Company Overview
    • 11.3.8.2 Role of F. Hoffmann-La Roche Ltd in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.8.3 Financials
    • 11.3.8.4 Recent Developments
    • 11.3.8.5 Analyst Perspective
  • 11.3.9 Hologic, Inc.
    • 11.3.9.1 Company Overview
    • 11.3.9.2 Role of Hologic, Inc. in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.9.3 Financials
    • 11.3.9.4 Recent Developments
    • 11.3.9.5 Analyst Perspective
  • 11.3.10 QIAGEN N.V.
    • 11.3.10.1 Company Overview
    • 11.3.10.2 Role of QIAGEN N.V. in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.10.3 Financials
    • 11.3.10.4 Recent Developments
    • 11.3.10.5 Analyst Perspective
  • 11.3.11 Thermo Fisher Scientific Inc.
    • 11.3.11.1 Company Overview
    • 11.3.11.2 Role of Thermo Fisher Scientific Inc. in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.11.3 Financials
    • 11.3.11.4 Recent Developments
    • 11.3.11.5 Analyst Perspective
  • 11.3.12 Siemens Healthineers AG
    • 11.3.12.1 Company Overview
    • 11.3.12.2 Role of Siemens Healthineers AG in the India Emerging Infectious Disease Diagnostics Market
    • 11.3.12.3 Financials
    • 11.3.12.4 Recent Developments
    • 11.3.12.5 Analyst Perspective
• 11.4 Emerging Company Snapshots
  • 11.4.1 Trivitron Healthcare
    • 11.4.1.1 Company Overview
  • 11.4.2 Genes2Me
    • 11.4.2.1 Company Overview
  • 11.4.3 CrisprBits
    • 11.4.3.1 Company Overview
  • 11.4.4 D-NOME Pvt Ltd
    • 11.4.4.1 Company Overview

List of Figures

• Figure 1: India Emerging Infectious Disease Diagnostics Market, $Million, 2022-2033
• Figure 2: India Emerging Infectious Disease Diagnostics Market: Drivers, Restraints, and Opportunities
• Figure 3: India Emerging Infectious Disease Diagnostics Market, Impact Analysis
• Figure 4: India Emerging Infectious Disease Diagnostics Market (by Technology), Share (%), 2022 and 2033
• Figure 5: India Emerging Infectious Disease Diagnostics Market (by Application), Share (%), 2022 and 2033
• Figure 6: India Emerging Infectious Disease Diagnostics Market (by Type of Infection), Share (%), 2022 and 2033
• Figure 7: India Emerging Infectious Disease Diagnostics Market (by Disease Type), Share (%), 2022 and 2033
• Figure 8: Share of Key Developments, January 2019-June 2023
• Figure 9: India Emerging Infectious Disease Diagnostics Market Segmentation
• Figure 10: India Emerging Infectious Disease Diagnostics Market Research Methodology
• Figure 11: Primary Research Methodology
• Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 13: Top-Down Approach (Segment-Wise Analysis)
• Figure 14: India Emerging Infectious Disease Diagnostics Market, $Million, 2022-2033
• Figure 15: Incidence of Influenza A and B, India, Thousand, 2022-2033
• Figure 16: Diagnosis Rate of Influenza A and B, India, %, 2022-2033
• Figure 17: Target Patient Pool of Influenza A and B, India, Thousand, 2022-2033
• Figure 18: Incidence of RSV, India, Thousand, 2022-2033
• Figure 19: Diagnosis Rate of RSV, India, %, 2022-2033
• Figure 20: Target Patient Pool of RSV, India, 2022-2033
• Figure 21: Incidence of Mycoplasma Infections, India, Thousand, 2022-2033
• Figure 22: Diagnosis Rate of Mycoplasma Infections, India, %, 2022-2033
• Figure 23: Target Patient Pool of Mycoplasma Infections, India, Thousand, 2022-2033
• Figure 24: Incidence of Pertussis, India, 2022-2033
• Figure 25: Diagnosis Rate of Pertussis, India, %, 2022-2033
• Figure 26: Target Patient Pool of Pertussis, India, 2022-2033
• Figure 27: Incidence of Hepatitis B Infection, India, Thousand, 2022-2033
• Figure 28: Diagnosis Rate of Hepatitis B Infection, India, %, 2022-2033
• Figure 29: Target Patient Pool of Hepatitis B Infection, India, Thousand, 2022-2033
• Figure 30: Incidence of HIV-AIDS, India, Thousand, 2022-2033
• Figure 31: Diagnosis Rate of HIV-AIDS, India, %, 2022-2033
• Figure 32: Population Tested for HIV-AIDS, India, Thousand, 2022-2033
• Figure 33: Incidence of HPV, India, Thousand, 2022-2033
• Figure 34: Diagnosis Rate of HPV, India, %, 2022-2033
• Figure 35: Target Patient Pool of HPV, India, Thousand, 2022-2033
• Figure 36: Incidence of Herpes, India, Thousand, 2022-2033
• Figure 37: Diagnosis Rate of Herpes, India, %, 2022-2033
• Figure 38: Target Patient Pool of Herpes, India, Thousand, 2022-2033
• Figure 39: Incidence of Gonorrhea, India, Thousand, 2022-2033
• Figure 40: Diagnosis Rate of Gonorrhea, India, %, 2022-2033
• Figure 41: Target Patient Pool of Gonorrhea, India, Thousand, 2022-2033
• Figure 42: Incidence of Syphilis, India, Thousand, 2022-2033
• Figure 43: Diagnosis Rate of Syphilis, India, %, 2022-2033
• Figure 44: Target Patient Pool of Syphilis, India, Thousand, 2022-2033
• Figure 45: Incidence of Colitis, India, Thousand, 2022-2033
• Figure 46: Diagnosis Rate of Colitis, India, %, 2022-2033
• Figure 47: Target Patient Pool of Colitis, India, Thousand, 2022-2033
• Figure 48: Incidence of Peptic Ulcer, India, Thousand, 2022-2033
• Figure 49: Diagnosis Rate of Peptic Ulcer, India, %, 2022-2033
• Figure 50: Target Patient Pool of Peptic Ulcer, India, Thousand, 2022-2033
• Figure 51: Incidence of Diarrhea, India, Thousand, 2022-2033
• Figure 52: Diagnosis Rate of Diarrhea, India, %, 2022-2033
• Figure 53: Target Patient Pool of Diarrhea, India, Thousand, 2022-2033
• Figure 54: Incidence of Meningitis, India, Thousand, 2022-2033
• Figure 55: Diagnosis Rate of Meningitis, India, %, 2022-2033
• Figure 56: Target Patient Pool of Meningitis, India, Thousand, 2022-2033
• Figure 57: Incidence of Encephalitis, India, Thousand, 2022-2033
• Figure 58: Diagnosis Rate of Encephalitis, India, %, 2022-2033
• Figure 59: Target Patient Pool of Encephalitis, India, Thousand, 2022-2033
• Figure 60: Incidence of CMV Infection, India, 2022-2033
• Figure 61: Diagnosis Rate of CMV Infection, India, %, 2022-2033
• Figure 62: Target Patient Pool of CMV Infection, India, 2022-2033
• Figure 63: Incidence of Sepsis, India, Thousand, 2022-2033
• Figure 64: Diagnosis Rate of Sepsis, India, %, 2022-2033
• Figure 65: Target Patient Pool of Sepsis, India, Thousand, 2022-2033
• Figure 66: Microbe Resistance for Second Generation Antibiotics in India, %, 2018-2025
• Figure 67: Preventive Measures to Limit AMR
• Figure 68: Factors Contributing to Antimicrobial Resistance (AMR), India
• Figure 69: Timeline of Emerging Technologies for Infectious Disease Diagnostics
• Figure 70: Advantages of Emerging Infectious Disease Diagnostic Technologies
• Figure 71: Limitations of Emerging Infectious Disease Diagnostic Technologies
• Figure 72: Key Settings of POC Testing Deployment
• Figure 73: India Emerging Infectious Disease Diagnostics Market, Impact Analysis
• Figure 74: India Emerging Infectious Diseases Incidence, 2020-2022
• Figure 75: Advantages of Point-of-Care Tests in Molecular Diagnostics
• Figure 76: Advantages of INAAT over PCR
• Figure 77: Advantages of Digital PCR over Quantitative Real-Time PCR
• Figure 78: India Emerging Infectious Disease Diagnostics Market (by Application)
• Figure 79: India Emerging Infectious Disease Diagnostics Market (by Application), Share (%), 2022 and 2033
• Figure 80: India Emerging Infectious Disease Diagnostics Market (Laboratory Testing), $Million, 2022-2033
• Figure 81: Laboratory Testing, Test Volume, Million, 2022-2033
• Figure 82: India Emerging Infectious Disease Diagnostics Market (Point-of-Care Testing), $Million, 2022-2033
• Figure 83: Point-of-Care Testing, Test Volume, Million, 2022-2033
• Figure 84: India Emerging Infectious Disease Diagnostics Market (by Technology)
• Figure 85: India Emerging Infectious Disease Diagnostics Market (by Technology), Share (%), 2022 and 2033
• Figure 86: India Emerging Infectious Disease Diagnostics Market (PCR), $Million, 2022-2033
• Figure 87: Polymerase Chain Reaction(PCR), Test Volume, Million, 2022-2033
• Figure 88: India Emerging Infectious Disease Diagnostics Market (RT-PCR), $Million, 2022-2033
• Figure 89: Reverse Transcription PCR (RT-PCR), Test Volume, Thousand, 2022-2033
• Figure 90: India Emerging Infectious Disease Diagnostics Market (Digital PCR), $Million, 2022-2033
• Figure 91: Digital PCR, Test Volume, Thousand, 2022-2033
• Figure 92: India Emerging Infectious Disease Diagnostics Market (Immunodiagnostics), $Million, 2022-2033
• Figure 93: Immunodiagnostics, Test Volume, Million, 2022-2033
• Figure 94: India Emerging Infectious Disease Diagnostics Market (Isothermal Nucleic Acid Amplification Technology (INAAT)), $Million, 2022-2033
• Figure 95: Isothermal Nucleic Acid Amplification Technology (INAAT), Test Volume, Million, 2022-2033
• Figure 96: India Emerging Infectious Disease Diagnostics Market (Next-Generation Sequencing (NGS)), $Million, 2022-2033
• Figure 97: Next-Generation Sequencing (NGS), Test Volume, Million, 2022-2033
• Figure 98: India Emerging Infectious Disease Diagnostics Market (Other Technologies), $Million, 2022-2033
• Figure 99: Other Technologies, Test Volume, Million, 2022-2033
• Figure 100: India Emerging Infectious Disease Diagnostics Market (by Type of Infection)
• Figure 101: India Emerging Infectious Disease Diagnostics Market (by Type of Infection), Share (%), 2022 and 2033
• Figure 102: India Emerging Infectious Disease Diagnostics Market (Bacterial), $Million, 2022-2033
• Figure 103: Bacterial Infections, Test Volume, Million, 2022-2033
• Figure 104: India Emerging Infectious Disease Diagnostics Market (Viral), $Million, 2022-2033
• Figure 105: Viral Infections, Test Volume, Million, 2022-2033
• Figure 106: India Emerging Infectious Disease Diagnostics Market (Fungal), $Million, 2022-2033
• Figure 107: Fungal Infections, Test Volume, Million, 2022-2033
• Figure 108: India Emerging Infectious Disease Diagnostics Market (Other Infections), $Million, 2022-2033
• Figure 109: Other Infections, Test Volume, Million, 2022-2033
• Figure 110: India Emerging Infectious Disease Diagnostics Market (by Disease Type)
• Figure 111: India Emerging Infectious Disease Diagnostics Market (by Disease Type), Share (%), 2022 and 2033
• Figure 112: India Emerging Infectious Disease Diagnostics Market (Respiratory Infections), $Million, 2022-2033
• Figure 113: Respiratory Infections, Test Volume, Million, 2022-2033
• Figure 114: India Emerging Infectious Disease Diagnostics Market (Gastrointestinal Infections), $Million, 2022-2033
• Figure 115: Gastrointestinal Infections, Test Volume, Million, 2022-2033
• Figure 116: India Emerging Infectious Disease Diagnostics Market (Sexually Transmitted Infections (STIs)), $Million, 2022-2033
• Figure 117: Sexually Transmitted Infections, Test Volume, Million, 2022-2033
• Figure 118: India Emerging Infectious Disease Diagnostics Market (Neurological Infections), $Million, 2022-2033
• Figure 119: Neurological Infections, Test Volume, Million, 2022-2033
• Figure 120: India Emerging Infectious Disease Diagnostics Market (Post-Transplant Infections), $Million, 2022-2033
• Figure 121: Post-Transplant Infections, Test Volume, Million, 2022-2033
• Figure 122: India Emerging Infectious Disease Diagnostics Market (Other Infections), $Million, 2022-2033
• Figure 123: Other Infections, Test Volume, Million, 2022-2033
• Figure 124: India Emerging Infectious Disease Diagnostics Market (by End User)
• Figure 125: India Emerging Infectious Disease Diagnostics Market (by End User), Share (%), 2022 and 2033
• Figure 126: India Emerging Infectious Disease Diagnostics Market (Hospitals and Clinics), $Million, 2022-2033
• Figure 127: Hospitals and Clinics, Test Volume, Million, 2022-2033
• Figure 128: India Emerging Infectious Disease Diagnostics Market (Diagnostic Laboratories), $Million, 2022-2033
• Figure 129: Diagnostic Laboratories, Test Volume, Million, 2022-2033
• Figure 130: India Emerging Infectious Disease Diagnostics Market (Other End Users), $Million, 2022-2033
• Figure 131: Other End Users, Test Volume, Million, 2022-2033
• Figure 132: Share of Key Developments, January 2019-June 2023
• Figure 133: Number of Mergers and Acquisitions (by Company), January 2019-June 2023
• Figure 134: Share of Synergistic Activities (by Company), January 2019-June 2023
• Figure 135: Number of Business Expansions and Funding Activities (by Company), January 2019-June 2023
• Figure 136: Number of Product Launches/Upgradations/Approvals (by Company), January 2019-June 2023
• Figure 137: Market Share Analysis for India Emerging Infectious Disease Diagnostics Market (by Company), 2022
• Figure 138: India Emerging Infectious Disease Diagnostics Market, Total Number of Companies Profiled
• Figure 139: Abbott Laboratories: Product Portfolio
• Figure 140: Abbott Laboratories: Overall Financials, $Million, 2020-2022
• Figure 141: Abbott Laboratories: Revenue (by Segment), $Million, 2020-2022
• Figure 142: Abbott Laboratories: Revenue (by Region), $Million, 2020-2022
• Figure 143: Abbott Laboratories: R&D Expenditure, $Million, 2020-2022
• Figure 144: Becton, Dickinson and Company (BD): Product Portfolio
• Figure 145: Becton, Dickinson and Company: Overall Financials, $Million, 2020-2022
• Figure 146: Becton, Dickinson and Company: Revenue (by Segment), $Million, 2020-2022
• Figure 147: Becton, Dickinson and Company: Revenue (by Region), $Million, 2020-2022
• Figure 148: Becton, Dickinson and Company: R&D Expenditure, $Million, 2020-2022
• Figure 149: bioMerieux S.A.: Product Portfolio
• Figure 150: bioMerieux S.A.: Overall Financials, $Million, 2020-2022
• Figure 151: bioMerieux S.A.: Revenue (by Segment), $Million, 2020-2022
• Figure 152: bioMerieux S.A.: Revenue (by Region), $Million, 2020-2022
• Figure 153: bioMerieux S.A.: R&D Expenditure, $Million, 2020-2022
• Figure 154: Bio-Rad Laboratories, Inc.: Product Portfolio
• Figure 155: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2020-2022
• Figure 156: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2020-2022
• Figure 157: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2020-2022
• Figure 158: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 159: Co-Diagnostics, Inc.: Product Portfolio
• Figure 160: DANAHER CORPORATION: Product Portfolio
• Figure 161: DANAHER CORPORATION: Overall Financials, $Million, 2020-2022
• Figure 162: DANAHER CORPORATION: Revenue (by Segment), $Million, 2020-2022
• Figure 163: DANAHER CORPORATION: Revenue (by Region), $Million, 2020-2022
• Figure 164: DANAHER CORPORATION: R&D Expenditure, $Million, 2020-2022
• Figure 165: DiaSorin S.p.A.: Product Portfolio
• Figure 166: DiaSorin S.p.A.: Overall Financials, $Million, 2021-2022
• Figure 167: DiaSorin S.p.A.: Revenue (by Region), $Million, 2021-2022
• Figure 168: DiaSorin S.p.A.: R&D Expenditure, $Million, 2021-2022
• Figure 169: F. Hoffmann-La Roche Ltd: Product Portfolio
• Figure 170: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
• Figure 171: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
• Figure 172: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
• Figure 173: Hologic, Inc.: Product Portfolio
• Figure 174: Hologic, Inc.: Overall Financials, $Million, 2020-2022
• Figure 175: Hologic, Inc.: Revenue (by Segment), $Million, 2020-2022
• Figure 176: Hologic, Inc.: Revenue (by Region), $Million, 2020-2022
• Figure 177: Hologic, Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 178: QIAGEN N.V.: Product Portfolio
• Figure 179: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
• Figure 180: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
• Figure 181: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
• Figure 182: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
• Figure 183: Thermo Fisher Scientific Inc.: Product Portfolio
• Figure 184: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
• Figure 185: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
• Figure 186: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
• Figure 187: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 188: Siemens Healthineers AG: Product Portfolio
• Figure 189: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
• Figure 190: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
• Figure 191: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
• Figure 192: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022

List of Tables

• Table 1: At-Home COVID-19 Kits Approved for Commercial Use by ICMR
• Table 2: Commercially Available RT-PCR Kits
• Table 3: Commercially Available NGS Panels/Kits